Carrie Treadwell, MA

Carrie Treadwell, MA

Ms. Treadwell is Senior Director of Research for the National Brain Tumor Society (NBTS) and Managing Director of Defeat GBM Research Collaborative, a subsidiary of NBTS. She joined the organization in 1998. In these roles, Ms. Treadwell interacts with leading researchers and institutions to guide the development and success of key research initiatives, including overseeing the NBTS’s grant process. Under her management the grant portfolio grew from $2 million to over $36 million and the research program expanded into the international market.

Daniel C. Sullivan, M.D.

Daniel C. Sullivan, M.D.

Dr. Sullivan is Professor and Vice Chair for Research, Department of Radiology at Duke University Medical Center, and also Science Adviser to the Radiological Society of North America (RSNA). He completed radiology residency and nuclear medicine fellowship in 1977 at Yale-New Haven Hospital. From 1977 to 1997 Dr. Sullivan was in academic radiology, holding faculty appointments at Yale University Medical Center, Duke University Medical Center, and University of Pennsylvania Medical Center, before joining the National Cancer Institute at NIH in 1997. From 1997 to 2007 Dr.

Wendy K.D. Selig, MS

Wendy K.D. Selig, MS

Ms. Selig is President and CEO of the Melanoma Research Alliance (MRA), a public charity focused on finding and funding the most promising melanoma research worldwide that will accelerate progress toward a cure.  Ms. Selig drives and manages MRA’s strategic priorities, research portfolio, and day-to-day operations. Under her leadership, the MRA is accelerating progress toward a cure for melanoma by supporting an international, cross-disciplinary group of biomedical researchers exploring, identifying, and pursuing innovative, transformative research. 

Richard L. Schilsky, M.D., FASCO

Richard L. Schilsky, M.D., FASCO

Dr. Schilsky earned his MD degree at the University of Chicago Pritzker School of Medicine in 1975. Following a residency in Internal Medicine at the University of Texas Southwestern Medical Center and Parkland Memorial Hospital, he received training in Medical Oncology and Clinical Pharmacology at the National Cancer Institute (NCI) from 1977 to 1981. He then served as Assistant Professor of Medicine at the University of Missouri-Columbia School of Medicine from 1981-1984 when he returned to the University of Chicago. At the University of Chicago, Dr.

Wendy Sanhai, Ph.D., M.B.A.

Wendy Sanhai, Ph.D., M.B.A.

Dr. Sanhai’s extensive experience in biomedical research and regulatory science ranges from the basic research, to teaching, to technology and business development, to the design, implementation, and management of large-scale strategic collaborations at NIH, the Foundation for NIH (FNIH), and FDA and medical product development in industry. She has held key leadership roles in academia; at federal research and regulatory organizations; and, most recently, with regulated industry.

Mollie Roth, JD, LLM

Mollie Roth, JD, LLM

Ms. Roth is the Managing Partner of PGx Consulting, which provides bespoke business services to growing life sciences and biotech companies, with a specialty in the personalized medicine space. An attorney by training, She combines her expertise in business development, law and communications to provide highly customized, cost effective solutions to her clients.

Steven J. Potts, Ph.D., M.B.A.

Steven J. Potts, Ph.D., M.B.A.

Dr. Potts joined Flagship from Aperio, where he was Vice President of Life Sciences. He managed worldwide sales and marketing in the biopharma segment, where his team achieved global adoption by nearly all of the largest pharmaceutical companies. He defined and led the GLP product development and validation services for the use of whole slide images in regulated preclinical and clinical trials studies, as well as the development of image analysis techniques for angiogenesis.

Lynn Matrisian, Ph.D., M.B.A.

Lynn Matrisian, Ph.D., M.B.A.

Dr. Matrisian is Vice President of Scientific & Medical Affairs at the Pancreatic Cancer Action Network, based in Manhattan Beach, California. She is formerly Professor and the founding Chair of the Department of Cancer Biology at Vanderbilt University School of Medicine and the Vanderbilt Ingram Cancer Center in Nashville, Tennessee.

Nola Hylton, Ph.D.

Nola Hylton, Ph.D.

Dr. Hylton is Professor of Radiology and Biomedical lmaging at University of California, San Francisco. Her research focuses on the development and clinical optimization of magnetic resonance imaging (MRI) for breast cancer detection, diagnosis and staging. Dr. Hylton serves as Principal Investigator for the multi-center American College of Radiology Imaging Network (ACRIN) clinical trials 6657 and 6698, evaluating advanced breast MRI techniques for assessing breast cancer response to pre-operative chemotherapy.  Dr.

Pages

Subscribe to National Biomarker Development Alliance (NBDA) RSS